Springer Nature, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand.
Drugs. 2022 Jul;82(10):1137-1141. doi: 10.1007/s40265-022-01740-0. Epub 2022 Jul 7.
Serplulimab () is an intravenously administered anti-PD-1 antibody being developed by Shanghai Henlius Biotech, Inc. for the treatment of solid tumours. Anti-PD-1 immunotherapies, such as serplulimab, can stimulate immune responses by relieving PD-1-related immunosuppression. Serplulimab received its first approval on 25 Mar 2022 in China for the treatment of adult patients with advanced unresectable or metastatic microsatellite instability-high (MSI-H) solid tumours that have failed to respond to previous standard treatments. This article summarizes the milestones in the development of serplulimab leading to this first approval in the treatment of MSI-H solid tumours in adults.
赛普利单抗（）是上海和黄药业有限公司开发的一种静脉注射用抗 PD-1 抗体，用于治疗实体瘤。抗 PD-1 免疫疗法，如赛普利单抗，可以通过缓解 PD-1 相关的免疫抑制来刺激免疫反应。赛普利单抗于 2022 年 3 月 25 日在中国首次获批，用于治疗既往标准治疗失败的不可切除或转移性微卫星高度不稳定（MSI-H）成人晚期实体瘤。本文总结了赛普利单抗的发展里程碑，最终该药在中国获批用于治疗 MSI-H 成人晚期实体瘤。
